KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Efficacy and safety of ilaprazole for stress ulcer - associated upper gastrointestinal bleeding prophylaxis in critically ill patients: a randomized, double-blind, non-inferiority phase 3 trial.

Jiao Liu, Xiaojun Pan, Sisi Huang, Shouzhi Fu, Yannan Cui, Jingwen Yang, Xuemei Hou, Ying Xia, Sheng Zhang, Zhenliang Wen, Hong Sun, Yi Xiao, Hui Li, Weifeng Shang, Xiangyou Yu, Dechang Chen

Ann Intensive Care 16 100044

PMID41852672
PMCIDPMC12993241
DOI10.1016/j.aicoj.2026.100044
发表日期2026-03-19
摘要

摘要

OBJECTIVES: To evaluate the efficacy and safety of Ilaprazole in preventing stress ulcer-associated upper gastrointestinal bleeding in critically ill patients. DESIGN: A Randomized, Double-Blind, non-inferiority Phase 3 Trial. SETTING: 70 hospitals across China from July 16, 2021, to April 28, 2022. PATIENTS: 441 Patients (mean age 59 years; 150 female) at high risk for stress ulcer bleeding requiring invasive mechanical ventilation were enrolled. INTERVENTIONS: Patients were randomly assigned to receive either Ilaprazole (10 mg once daily, first dose doubled; 220 patients) or esomeprazole (40 mg twice daily; 221 patients). MEASUREMENTS AND MAIN RESULTS: 441 patients (mean age 59 years; 150 female) were enrolled: 220 received Ilaprazole and 221 received esomeprazole. In FAS set, the primary endpoint occurred in 213 (96.80%) patients in the Ilaprazole and 215 (97.30%) in esomeprazole arms (Absolute Risk Difference: -0.47, 95% CI: -4.02, 3.03, p = 0.772). Secondary outcomes showed comparable incidences of clinically insignificant UGI bleeding, any gastrointestinal bleeding, 28-day mortality, ICU mortality, and pneumonitis. Adverse events were similar between groups, but Ilaprazole had a significantly lower incidence of hepatobiliary disorders (0.9% vs. 5%, p = 0.012). CONCLUSIONS: Ilaprazole demonstrated non-inferiority to esomeprazole in preventing UGI bleeding in critically ill patients at high risk of stress ulcer.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。